Your browser doesn't support javascript.
loading
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
Papadimitrakopoulou, V A; Mok, T S; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, Y-L.
Afiliação
  • Papadimitrakopoulou VA; Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, USA.
  • Mok TS; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Han JY; Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea.
  • Ahn MJ; Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Delmonte A; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.
  • Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine Winship Cancer Institute, Atlanta, USA.
  • Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Shepherd FA; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Ontario, Canada; Department of Medical Oncology and Hematology, The University of Toronto, Ontario, Canada.
  • Laskin J; Department of Medicine, BC Cancer Agency, Vancouver, British Columbia, Canada.
  • He Y; Department of Respiratory Disease, Daping Hospital, Chongqing, People's Republic of China.
  • Akamatsu H; Internal Medicine III, Wakayama Medical University Hospital, Wakayama, Japan.
  • Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Su WC; Department of Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.
  • John T; Department of Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia.
  • Sebastian M; Department of Medicine, Hematology and Oncology, University Hospital Frankfurt, Frankfurt, Germany.
  • Mann H; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Miranda M; Oncology R&D, AstraZeneca, Cambridge, UK.
  • Laus G; Global Medicines Development, AstraZeneca, Cambridge, UK.
  • Rukazenkov Y; Global Medicines Development, AstraZeneca, Cambridge, UK.
  • Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. Electronic address: syylwu@live.cn.
Ann Oncol ; 31(11): 1536-1544, 2020 11.
Article em En | MEDLINE | ID: mdl-32861806
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Tipo de estudo: Clinical_trials Limite: Adult / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos